Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Haloprogin: a topical antifungal agent.

E F Harrison, P Zwadyk, R J Bequette

    Applied Microbiology
    |May 1, 1970
    PubMed
    Summary
    This summary is machine-generated.

    Related Concept Videos

    You might also read

    Related Articles

    Articles linked to this work by shared authors, journal, and citation graph.

    Sort by
    Same author

    A randomised feasibility trial comparing needle fasciotomy with limited fasciectomy treatment for Dupuytren's contractures.

    Pilot and feasibility studies·2020
    Same author

    The views of children and young people on the use of silk garments for the treatment of eczema: a nested qualitative study within the CLOTHing for the relief of Eczema Symptoms (CLOTHES) randomized controlled trial.

    The British journal of dermatology·2017
    Same author

    Discussion on Proprietary and Secret Remedies.

    Proceedings of the Royal Society of Medicine·2009
    Same author

    The spindle checkpoint of the yeast Saccharomyces cerevisiae requires kinetochore function and maps to the CBF3 domain.

    Genetics·2001
    Same author

    Cell cycle arrest in cdc20 mutants of Saccharomyces cerevisiae is independent of Ndc10p and kinetochore function but requires a subset of spindle checkpoint genes.

    Genetics·1998
    Same author

    Differential requirements for DNA replication in the activation of mitotic checkpoints in Saccharomyces cerevisiae.

    Molecular and cellular biology·1997

    Haloprogin effectively treats topical fungal infections in guinea pigs, showing broad-spectrum activity against yeasts and bacteria. It demonstrates comparable antifungal efficacy to tolnaftate but with added antimonilial and antibacterial benefits.

    Area of Science:

    • Mycology
    • Dermatology
    • Antimicrobial research

    Background:

    • Topical mycotic infections require effective antifungal agents.
    • Haloprogin and tolnaftate are topical antifungal agents with distinct activity profiles.

    Purpose of the Study:

    • To evaluate the efficacy of haloprogin against experimentally induced topical mycotic infections.
    • To compare the in vitro and in vivo activity spectrum of haloprogin with tolnaftate.

    Main Methods:

    • Experimental induction of topical mycotic infections in guinea pigs.
    • In vitro susceptibility testing against yeasts, Candida species, gram-positive bacteria, and dermatophytes.
    • Comparative efficacy assessment with tolnaftate in vivo and in vitro.

    Main Results:

    Related Experiment Videos

    • Haloprogin demonstrated high efficacy in treating topical mycotic infections in guinea pigs.
    • In vitro, haloprogin was active against yeasts, Candida, and gram-positive bacteria, with antifungal activity comparable to tolnaftate against dermatophytes.
    • Haloprogin exhibited significant antimonilial and selective antibacterial activity, unlike tolnaftate.
    • Serum reduced haloprogin's in vitro antifungal activity more than tolnaftate's, but topical application showed no diminished efficacy.

    Conclusions:

    • Haloprogin possesses a broad spectrum of antimicrobial activity, including antifungal, antimonilial, and antibacterial properties.
    • Its efficacy against dermatophytes in vivo was not diminished by serum, suggesting clinical potential.
    • Haloprogin may be a superior topical agent for treating human dermatophytic and monilial infections.